Seer, Inc. and Korea University Launch First | U.S. Finance News
Seer and Korea University launch a research to determine blood-based most cancers biomarkers utilizing superior mass spectrometry and AI analytics.Quiver AI AbstractSeer, Inc. and Korea University have launched a groundbreaking population-level research geared toward figuring out blood-based biomarkers for early-onset most cancers in younger adults aged 20 to 30. Utilizing Seer’s Proteograph ONE Assay and superior mass spectrometry, the research will analyze 20,000 plasma samples—15,000 from most cancers sufferers and 5,000 from healthy controls—sourced from main most cancers establishments in Korea. This initiative, funded by the Ok-Health MIRAE program, represents the primary large-scale plasma proteomics effort that employs mass spectrometry and AI to reinforce early most cancers detection. The Proteograph ONE workflow enhances the effectivity and depth of proteomic evaluation, processing over 1,000 samples per week whereas delivering a better identification of proteins in comparison with typical strategies. The collaboration goals to drive developments in diagnostics, enabling early interventions and bettering outcomes for younger most cancers sufferers.
Potential Positives
Potential Negatives
FAQWhat is the purpose of Seer’s new population-level research?The research goals to determine novel blood-based most cancers biomarkers for younger adults of their 20s and 30s.How does the Proteograph ONE Assay improve proteomic evaluation?This assay accelerates evaluation and reduces prices, enabling large-scale research and enhancing early most cancers detection.Which establishments are concerned in accumulating plasma samples?The research consists of samples from Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center.What technology helps the proteomic evaluation on this research?The research makes use of Seer’s Proteograph ONE workflow and Thermo Scientific’s Orbitrap Astral mass spectrometer for superior proteomic insights.Why is that this research thought-about groundbreaking for most cancers diagnostics?It leverages AI-driven analytics and mass spectrometry, aiming for more delicate, scalable, and personalised most cancers diagnostics for younger adults.
Disclaimer: This is an AI-generated abstract of a press release distributed by GlobeNewswire. The model used to summarize this release might make errors. See the complete release right here.
$SEER Insider Trading Activity$SEER insiders have traded $SEER stock on the open market 4 instances prior to now 6 months. Of these trades, 0 have been purchases and 4 have been gross sales.Here’s a breakdown of latest trading of $SEER stock by insiders over the past 6 months:
To observe insider transactions, take a look at Quiver Quantitative’s insider trading dashboard.$SEER Hedge Fund ActivityWe have seen 20 institutional buyers add shares of $SEER stock to their portfolio, and 45 lower their positions of their most up-to-date quarter.
Here are some of the most important latest strikes:
To observe hedge funds’ stock portfolios, take a look at Quiver Quantitative’s institutional holdings dashboard.Full Release
First-of-its-kind research will use Seer’s next-generation workflow to determine early-onset most cancers biomarkers and energy deep, unbiased mass spectrometry-based proteomics
Seer’s new Proteograph ONE Assay to speed up evaluation and scale back prices, making large-scale research possible
REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted companion for deep, unbiased proteomic insights, and Korea University, a main analysis establishment dedicated to innovation and international affect, at this time introduced the launch of a population-level research geared toward figuring out novel blood-based biomarkers that might result in most cancers diagnostics for younger adults of their 20s and 30s. Relying on Seer’s newly launched Proteograph
®
ONE Assay and SP200 Automation Instrument together with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, that is the primary large-scale plasma proteomics initiative of its form to leverage mass spectrometry and AI-driven analytics to reinforce early most cancers detection and improve affected person outcomes.
Seer’s latest platform advances will enable deep, unbiased proteomic evaluation of 20,000 plasma samples in much less time and price than has ever earlier than been doable. These will embody samples from 15,000 most cancers sufferers and 5,000 healthy sufferers that can function controls, sourced from Korea’s main most cancers establishments: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year research is funded by the Ok-Health MIRAE initiative below the Ministry of Health and Welfare, Republic of Korea, which helps formidable, high-impact health analysis.
“We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer’s Proteograph platform—and Seer’s assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,” stated Professor Sang-Won Lee on the Center of Proteogenome Research (CPGR) of Korea University. “The unique combination of Seer’s latest platform and CPGR’s proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.”
By leveraging the facility of deep proteomic evaluation, this research goals to catalyze a new wave of diagnostics which can be more delicate, scalable, and personalised—finally driving earlier interventions and bettering survival outcomes in younger grownup most cancers sufferers worldwide.
Transformational Technology for Population-Scale Proteomics
At the center of the research is Seer’s Proteograph ONE workflow, launched this week on the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically will increase scale and effectivity in proteomic evaluation by:
“Korea University selected Seer’s new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,” stated Omid Farokhzad, Chair and CEO of Seer. “We’re excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.”
The research additionally employs Thermo Scientific’s Orbitrap Astral MS—the industry’s main mass spectrometer for proteomic analysis. The Proteograph choices mixed with the Orbitrap Astral MS present a deep, full-range plasma proteome evaluation at quicker speeds to allow crucial breakthrough discoveries in large-population research.
“When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,” stated Dan Shine, senior vice president and president of analytical devices, Thermo Fisher Scientific. “We’re proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.”
The next-generation choices mark a important evolution of the Proteograph Product Suite, delivering the size, velocity, and effectivity required to make population-level proteomics each sensible and accessible. The collaboration with Korea University exemplifies the real-world affect of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer’s platform can now inform large-scale research, speed up biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision drugs.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) units the usual in deep, unbiased proteomics—delivering insights with a scale, velocity, precision, and reproducibility beforehand unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and superior analytical software program to unravel challenges typical strategies have failed to beat. Traditional proteomic applied sciences have struggled with inconsistent knowledge, restricted throughput, and prohibitive complexity, however Seer’s strong and scalable workflow persistently reveals organic insights that others can’t. Seer’s merchandise are for analysis use solely and should not meant for diagnostic procedures. For more details about Seer’s differentiated strategy and ongoing management in proteomics, go to
www.seer.bio
.
Media Contact:
Consort Partners
[email protected]
Investor Contact:
Carrie Mendivil
[email protected]
This article was initially printed on Quiver News, learn the complete story.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
Stay up to date with the latest news within the US markets! Our web site is your go-to source for cutting-edge financial news, market trends, financial insights, and updates on home trade. We present each day updates to make sure you have entry to the freshest info on stock market actions, commodity costs, currency fluctuations, and main financial bulletins.
Explore how these trends are shaping the longer term of the US financial system! Visit us often for essentially the most partaking and informative market content material by clicking right here. Our fastidiously curated articles will keep you knowledgeable on market shifts, investment methods, regulatory modifications, and pivotal moments within the US financial panorama.
